CME Presentations

Prostate Cancer



  • Michael Gorin, MD

    Michael Gorin, MD

    Michael Gorin, MD


    Michael Gorin, MD, is a urologist practicing at Urology Associates and UPMC Western Maryland and a Clinical Assistant Professor of Urology at the University of Pittsburgh School of Medicine. He’s an internationally recognized expert on the use of molecular imaging techniques in the management of urologic malignancies. His research includes studying PSMA-targeted PET imaging of prostate and kidney cancer and 99mTc-sestamibi SPECT imaging of small renal tumors. Dr. Gorin is also known for his work developing novel methods for performing MRI-guided transperineal prostate biopsy and focal ablative treatments of prostate cancer. Also, he is the Chief Global Advisor on Medical Affairs to KOELIS, Inc., a world leader in the use of 3D ultrasound technology for performing urologic procedures.
  • Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Medical Director, CPI

    Neal Shore, MD, is the Medical Director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 400 clinical trials, focusing on GU Oncology indications. He is the Chief Medical Officer, Surgery/Urology, for GenesisCare,US. Dr. Shore serves on the SITC Guidelines Committee for Bladder Cancer and the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the Chair of the LUGPA Education Committee. Dr. Shore is on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, World Journal of Urology, and serves as Editor for Everyday Urology-Oncology. Also, he’s a Fellow of the American College of Surgeons.

CME Information

PIM LogoPQH Logo

Expanding the Role of Radiopharmaceuticals for Prostate Cancer Management

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with ZERO – The End of Prostate Cancer (ZERO).


This activity is supported by educational grants from Lantheus Medical Imaging, Blue Earth Diagnostics, and Applied Accelerator Applications, a division of Novartis


This activity was released on May 3, 2022 and is valid until May 3, 2023. Requests for credit must be made no later than May 3, 2023.


The target audiences for the proposed HCP activity are urologists; radiation, surgical, and medical oncologists; radiologists; nuclear medicine specialists; pathologists; and other HCPs interested/involved in the diagnostic and therapeutic management of patients with prostate cancer.


Prostate cancer is the second most common cancer affecting men in the US, with approximately 1 in 8 men expected to be diagnosed with prostate cancer in their lifetimes. While significant treatment advances have been made, prostate-cancer mortality remains high and accurate diagnosis and staging are critical to provide timely interventions and optimize outcomes.

Newer imaging techniques using molecular radiotracers provide improved sensitivity, specificity, and accuracy compared to conventional modalities for prostate-cancer detection. While prostate-specific membrane antigen (PSMA) imaging shows clear clinical utility to identify disease earlier, it can still be difficult to determine which situations require PSMA PET/CT imaging to identify disease burden and redefine high-volume disease.

Join urologists and prostate-cancer experts Dr. Neal Shore and Dr. Michael Gorin to discuss the role of approved and emerging radiopharmaceuticals in the optimal management of prostate cancer. Panelists will compare newer radiotracers with conventional imaging and review recent safety and efficacy data on the integration of molecular imaging into all stages of prostate cancer.


After completing this activity, the participant should be better able to:
  • Outline clinical-trial data for approved and investigational radiotracers for prostate-cancer imaging
  • Evaluate clinical scenarios in which PSMA PET identifies disease burden beyond radionuclide bone scans and CT in order to identify disease recurrence in patients with prostate cancer
  • Analyze the safety and efficacy of emerging theranostic agents for the treatment of advance prostate cancer


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Dr. Neal Shore, MD
Medical Director, CPI, Carolina Urologic Research Center
Chief Medical Officer, Surgical Oncology and Urology, Genesis Care US
Consulting Fee (e.g., Advisory Board): AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boston Scientific, Clarity, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, Lantheus, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Photocure, Propella, PreView, Sanofi Genzyme, Specialty Networks, Sesen Bio, Telix, Tolmar, Urogen, Vaxiion
Dr. Michael A. Gorin, MD
Clinical Assistant Professor of Urology,
University of Pittsburgh School of Medicine
Staff Urologist, Urology Associates
& UPMC Western Maryland, Cumberland, MD
Consulting Fee (e.g., Advisory Board): Blue Earth Diagnostics, Inc., BK Medical, OBP Medical, Corbin Clinical Resources, Inc. (Perineologic), KOELIS Inc., Ambu A/S, Galvanize Therapeutics, Lantheus Medical, Telix Pharmaceuticals
Contracted Research: KOELIS, Inc., MIM Software
Speakers' Bureau: Lantheus Medical Imaging, Inc.
Stock Option Holder: Simulated Inanimate Models, LLC
Royalty: Precision Molecular

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Eve Wilson Nothing to disclose
Caroline Laurendeau Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support: For any technical issues or issues with your CME Certificate, please contact CancerCoachLive, OMedLive or UroCareLive at 877-394-1306 or at, or